Salud financiera de hoja de balance de Icosavax

Salud financiera controles de criterios 6/6

Icosavax tiene un patrimonio de los accionistas total de $232.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $251.3M y $18.9M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$229.21m
Patrimonio	US$232.38m
Total pasivo	US$18.92m
Activos totales	US$251.30m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Recent updates

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Jul 04

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Mar 10

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Oct 18

Icosavax GAAP EPS of -$0.57

Aug 15

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($235.3M) de ICVX superan a sus pasivos a corto plazo ($13.0M).

Pasivo a largo plazo: Los activos a corto plazo de ICVX ($235.3M) superan a sus pasivos a largo plazo ($5.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ICVX está libre de deudas.

Reducción de la deuda: ICVX no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ICVX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ICVX dispone de suficiente cash runway para 1.9 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 51.6% cada año.

Salud financiera de hoja de balance de Icosavax

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Icosavax Files Form 15

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera